An overview of systematic reviews of pharmacological and non-pharmacological interventions for the treatment of behavioral and psychological symptoms of dementia

Dyer, Suzanne M; Harrison, Stephanie L; Laver, Kate; Whitehead, Craig; Crotty, Maria

doi:10.1017/s1041610217002344

Cited by 259 publications

(228 citation statements)

References 35 publications

(67 reference statements)

Supporting

Mentioning

213

Contrasting

Unclassified

Order By: Relevance

“…While there are pharmacologic interventions to clearly improve psychosis and aggressive symptoms, nonpharmacologic interventions for patients and their caregivers might have also improved their depressive mood or emotional withdrawal, which may, in turn, decrease overall NPS severity. [27][28][29] When treating NPSs with antipsychotics, which target psychosis or aggression, clinicians may also need to pay attention to motivational and emotional problems and monitor early cognitive declines.…”

Section: Discussionmentioning

confidence: 99%

“…Third, the influence of medication dosage was not taken into account since flexible dosing was employed in the original CATIE-AD study. 13 Fourth, the antidepressant or anticonvulsant effectiveness for overall NPSs has been shown in a recent systematic review, 28 but we did not include concomitant medications (ie, psychotropics, anticholinesterase drugs, or antihypertensive drugs) prior to the trial initiation as confounding factors in the present study. Although they may have influence as clinical predictors of subsequent response, we found no relationship between concomitant medications and subsequent treatment response in the previous reports of the CATIE-AD study.…”

Section: Limitationsmentioning

confidence: 99%

See 1 more Smart Citation

Early Improvements of Individual Symptoms With Antipsychotics Predict Subsequent Treatment Response of Neuropsychiatric Symptoms in Alzheimer’s Disease

Nagata

Shinagawa

Yoshida

et al. 2020

J. Clin. Psychiatry

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Limitationsmentioning

confidence: 99%

Early Improvements of Individual Symptoms With Antipsychotics Predict Subsequent Treatment Response of Neuropsychiatric Symptoms in Alzheimer’s Disease

Nagata

Shinagawa

Yoshida

et al. 2020

J. Clin. Psychiatry

View full text Add to dashboard Cite

“…For example, what is included in "music therapy" (Dyer et al, 2017)? Does it include listening to music via headphones?…”

Section: What Is a Non-pharmacological Intervention?mentioning

confidence: 99%

Non-pharmacological interventions for persons with dementia: what are they and how should they be studied?

Cohen‐Mansfield

2018

Int. Psychogeriatr.

View full text Add to dashboard Cite

The publication of four papers concerning non-pharmacological interventions for persons with dementia heralds progress in the science of dementia care. The four papers are very diverse in focus and methodology, and include a study of the impact of a visual arts program on quality of life, communication, and well-being by Windle et al. (2017); an overview of systematic reviews of pharmacological and non-pharmacological interventions for the treatment of behavioral and psychological symptoms of dementia by Dyer et al. (2017); a systematic review of the efficacy of intervention in people with Lewy body dementia by Morrin et al. (2017); and a protocol of the Behavior and Evolution of Young Onset Dementia part two (BEYOND-II) study, an intervention study aimed at improvement in the management of neuropsychiatric symptoms in institutionalized people with young onset dementia by van Duinen-van den IJssel et al. (2017).

show abstract

“…[2][3][4] Current evidence suggests that people with mild to moderate AT dementia are most likely to benefit from CEIs; however, those with severe dementia and other types of dementia can also benefit. [2][3][4] Current evidence suggests that people with mild to moderate AT dementia are most likely to benefit from CEIs; however, those with severe dementia and other types of dementia can also benefit.…”

mentioning

confidence: 99%

“…dementia and may reduce behavioural and psychological symptoms of dementia (BPSD). [2][3][4] Current evidence suggests that people with mild to moderate AT dementia are most likely to benefit from CEIs; however, those with severe dementia and other types of dementia can also benefit. Memantine can be added to CEIs or used in people with more advanced dementia.…”

mentioning

confidence: 99%

Antidementia medication use by aged care facility residents with dementia

Lind

Gray

Raban

et al. 2019

Int J Geriat Psychiatry

View full text Add to dashboard Cite

Objectives Little is known about the use of antidementia medications in Australia. Other countries have reported sociodemographic disparities in use. Our objective was to estimate prevalence, duration, and time to initiation of antidementia medication (cholinesterase inhibitors or memantine) among Australians with dementia in residential aged care facilities and to evaluate resident and facility factors associated with use. Methods Dynamic retrospective cohort study of people with dementia in 68 residential aged care facilities during 2014 to 2017 using electronic health record and medication administration data. Regression evaluated relationships between medication use (prevalence, duration, and time to initiation) and resident and facility characteristics. Results Five thousand three hundred fifty‐four residents with dementia were included in the analyses. Annual prevalence of antidementia medication use was less than 10% each year and decreased during the study period by 2‐percentage points by 2017 (relative to 2014). Antidementia medication use varied by sociodemographic characteristics (3‐points lower for single, 4‐points lower for divorced relative to married residents, and 3‐points higher for Australian‐born). Each point in ADL score was associated with 0.1‐point lower medication use. Antidementia medication use was lower in outer regional facilities. Most comorbidities were associated with lower antidementia medication use (myocardial infarction, cerebrovascular disease and heart failure 3‐points lower, respiratory disease, and diabetes 2‐points lower). Age had a complex relationship with antidementia medication use that varied by sex and if medication was started before or after admission. After admission, males initiated antidementia medication earlier than females. Conclusions Antidementia medication use in Australian facilities was lower than in other countries and varied by clinical and sociodemographic factors.

show abstract

An overview of systematic reviews of pharmacological and non-pharmacological interventions for the treatment of behavioral and psychological symptoms of dementia

Abstract: Background: This systematic overview reports findings from systematic reviews of randomized controlled trials of pharmacological and non-pharmacological interventions for behavioural and psychological symptoms of dementia (BPSD).

Cited by 259 publications

References 35 publications

Early Improvements of Individual Symptoms With Antipsychotics Predict Subsequent Treatment Response of Neuropsychiatric Symptoms in Alzheimer’s Disease

Early Improvements of Individual Symptoms With Antipsychotics Predict Subsequent Treatment Response of Neuropsychiatric Symptoms in Alzheimer’s Disease

Non-pharmacological interventions for persons with dementia: what are they and how should they be studied?

Antidementia medication use by aged care facility residents with dementia

Contact Info

Product

Resources

About